Inside a Cambridge laboratory, scientists have assembled something unprecedented: a genetic map of inflammatory bowel disease written in the language of individual cells. Researchers at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals NHS Foundation Trust have created IBDverse—the largest single-cell dataset ever compiled from gut tissue and blood—containing gene expression data from roughly 2.2 million individual cells. The work, published in Nature, reveals precisely how inherited genetic variations trigger the chronic inflammation that characterizes Crohn's disease and ulcerative colitis, diseases that together affect over 4.9 million people worldwide.
The breakthrough matters because IBD has long been a puzzle wrapped in a genetic mystery. Scientists knew that inherited DNA changes play a major role in determining who gets sick, yet over 90% of the genetic risk factors lie outside regions that code for proteins. For years, researchers could identify that disease-linked DNA variations existed without understanding how they actually harm people. The challenge was technical: most cellular studies blend tissue samples together, mixing dozens of cell types in one analysis and obscuring effects that only happen in specific cells—like spotting a single conversation in a crowded room.
To solve this, the team collected blood and gut samples from just over 400 individuals at Addenbrooke's Hospital in Cambridge, including 125 people with Crohn's disease. They carefully sampled the terminal ileum and rectum—the sites most commonly affected in Crohn's disease and ulcerative colitis respectively—and used single-cell RNA sequencing to measure gene expression in individual cells. The scale was staggering: measuring tens of thousands of genes across 2.2 million individual cells, then linking those measurements to known genetic risk regions for IBD.
What emerged was a map of disease written in specificity. Many genetic effects, the team discovered, only appear in particular cell types and vanish entirely when researchers study whole tissue samples. In immune cells called dendritic cells, genetic variations reduced Notch signaling—a pathway that normally helps regulate immune responses in the gut. Meanwhile, in epithelial cells that line the intestinal surface, the same genetic landscape dysregulated genes controlled by the Wnt pathway, disrupting the tissue renewal that keeps the gut lining intact. The picture crystallized: IBD arises from a dual failure—the immune system loses its ability to regulate itself, while the gut's lining loses its capacity to repair and renew itself.
The implications ripple outward. The study provides a molecular foundation for developing new treatments and repurposing existing ones. The researchers even identified an explanation for why metformin, the world's most commonly prescribed type 2 diabetes drug, frequently causes gastrointestinal side effects—a finding that could guide safer prescribing and drug design.
For the millions living with IBD, this map represents something vital: the moment when genetic complexity became cellular clarity. It transforms abstract risk factors into concrete biology, opening doors to treatments tailored to the specific cells and pathways driving disease in each person. The work exemplifies how single-cell science is fundamentally changing our ability to unlock disease mysteries.